Insulin Glargine API is a pharmaceutical-grade long-acting recombinant human insulin analog developed for the treatment of Type 1 Diabetes Mellitus and Type 2 Diabetes Mellitus. It provides a slow, steady release of insulin over approximately 24 hours, helping maintain consistent basal insulin levels and improving long-term glycemic control.
Following subcutaneous administration, Insulin Glargine forms microprecipitates in the subcutaneous tissue, allowing gradual insulin release with minimal peak activity. This prolonged pharmacokinetic profile reduces glucose fluctuations and supports once-daily dosing.
Manufactured under WHO-GMP-certified biopharmaceutical facilities, our Insulin Glargine API is produced using advanced recombinant DNA technology to ensure exceptional purity, biological activity, stability, and batch-to-batch consistency. Each batch undergoes comprehensive quality testing and is supplied with Certificate of Analysis (CoA), Material Safety Data Sheet (MSDS), Technical Data Sheet (TDS), and complete regulatory documentation.
Insulin Glargine API is used in injectable pharmaceutical formulations for long-term basal insulin therapy in patients with Type 1 and Type 2 Diabetes Mellitus.
Insulin Glargine forms microprecipitates after injection, releasing insulin slowly over approximately 24 hours to provide stable blood glucose control with minimal peak effect.
Yes. We provide CoA, MSDS, Technical Data Sheet (TDS), Product Specifications, and complete regulatory documentation with every shipment.
Yes. We supply Insulin Glargine API in commercial quantities for pharmaceutical and biopharmaceutical manufacturing worldwide.
Get Bulk Quote via WhatsApp